Relief Therapeutics Ownership
| RLF Stock | CHF 5.10 0.06 1.19% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Relief |
Relief Stock Ownership Analysis
About 22.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relief Therapeutics has Price/Earnings (P/E) ratio of 277.0. The entity recorded a loss per share of 0.01. The firm had not issued any dividends in recent years. Relief Therapeutics had 400:1 split on the 3rd of May 2023. Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. RELIEF THERAPEUTICS operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 10 people. To find out more about Relief Therapeutics Holding contact the company at 41 44 723 59 59 or learn more at https://www.relieftherapeutics.com.Relief Therapeutics Outstanding Bonds
Relief Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Relief Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Relief bonds can be classified according to their maturity, which is the date when Relief Therapeutics Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relief Stock Analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.